Peptide field guide
ELABELA
ELABELA (ELA) is an endogenous peptide signal studied in development and cardiovascular biology. A 2026 study linked lower ELA levels to fetal congenital heart disease and proposed a mitochondria-related mechanism in cardiac progenitor cells.
What it is
ELABELA (often shortened to ELA) is an endogenous peptide involved in developmental and cardiovascular signaling. In recent literature it has been studied in the context of heart development and pregnancy-associated biology.
Why people care about it
In 2026, researchers reported that ELA levels were lower in human fetal cardiac tissues with congenital heart disease and lower in maternal plasma in pregnancies affected by fetal congenital heart disease, alongside mouse evidence linking ELA to mitochondrial function in cardiac progenitor cells.
This makes ELA interesting as a potential biomarker candidate and as a mechanistic handle on how mitochondrial health intersects with heart development.
What we know vs what we don’t know
What we know:
- A 2026 study reported reduced ELA levels in human congenital heart disease fetal tissue and in maternal plasma in affected pregnancies.
- Mouse genetic and intervention experiments in that report supported a role for ELA in cardiac development, with a mitochondria-related mechanism proposed.
What we don’t know:
- Whether ELA will replicate as a clinically useful biomarker across populations and assay platforms.
- Whether any intervention concept is safe or feasible in humans.
Latest updates
- 2026-04-07: ELABELA linked to congenital heart disease via mitochondrial mechanism; exogenous ELA reduced severity/incidence in mice. https://pubmed.ncbi.nlm.nih.gov/41944334/
Safety reality
ELABELA is not an approved drug. Treat any non-regulated products claiming to be ELA/ELABELA as high risk.